# Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)

> **NCT00095069** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 600 (—)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** MK0928, gaboxadol / Duration of Treatment - 1 year
- **DRUG:** Comparator: placebo / Duration of Treatment -1 year

## Key facts

- **NCT ID:** NCT00095069
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 600 (—)
- **Last updated:** 2015-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095069, "Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00095069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*